Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review.
Eoghan R MaloneReeta BaruaNicholas MetiXuan LiRouhi FazelzadAaron Richard HansenPublished in: Cancer medicine (2021)
The quality of reporting of PROs in ICI phase II and III clinical trials is heterogeneous across various cancer sites. As PRO data are increasingly used to counsel patients and complement clinical decision making, innovative and collaborative efforts are required to improve the reporting of these essential data.
Keyphrases
- clinical trial
- phase ii
- patient reported outcomes
- quality improvement
- open label
- decision making
- electronic health record
- end stage renal disease
- newly diagnosed
- phase iii
- papillary thyroid
- prognostic factors
- double blind
- study protocol
- emergency department
- peritoneal dialysis
- randomized controlled trial
- young adults
- lymph node metastasis